Global Pet Skin Disease Drugs 麻豆原创 Growth 2025-2031

Publication ID:

LPI02254176

Publication Date:

February 27, 2025

Pages:

109

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Pet Skin Disease Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Pet skin disease drugs refer to medications and treatments specifically formulated to address various skin conditions in pets, such as dogs and cats. These drugs are prescribed by veterinarians and can be used to treat a range of skin issues, including infections, allergies, parasites, inflammation, and other dermatological disorders.
United States market for Pet Skin Disease Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Pet Skin Disease Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Pet Skin Disease Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Pet Skin Disease Drugs players cover Zoetis Animal Health, Boehringer Ingelheim, Elanco, Virbac, Norbrook Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧et Skin Disease Drugs Industry Forecast鈥� looks at past sales and reviews total world Pet Skin Disease Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Pet Skin Disease Drugs sales for 2025 through 2031. With Pet Skin Disease Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pet Skin Disease Drugs industry.
This Insight Report provides a comprehensive analysis of the global Pet Skin Disease Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pet Skin Disease Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Pet Skin Disease Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pet Skin Disease Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pet Skin Disease Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Pet Skin Disease Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Internal Medication
External Medication
Segmentation by Application:
Parasitic Skin Diseases
Fungal Dermatoses
Bacterial Skin Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Zoetis Animal Health
Boehringer Ingelheim
Elanco
Virbac
Norbrook Laboratories
Dechra Veterinary Products
Vetoquinol
ALKINLAB
Truseb
Olewo
KANGZHIBO
Shanghai Hanvet Bio-Pharm
DCVET
Nanjing LANBOTO
Jindun Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pet Skin Disease Drugs market?
What factors are driving Pet Skin Disease Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pet Skin Disease Drugs market opportunities vary by end market size?
How does Pet Skin Disease Drugs break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Pet Skin Disease Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pet Skin Disease Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pet Skin Disease Drugs by Country/Region, 2020, 2024 & 2031
2.2 Pet Skin Disease Drugs Segment by Type
2.2.1 Internal Medication
2.2.2 External Medication
2.3 Pet Skin Disease Drugs Sales by Type
2.3.1 Global Pet Skin Disease Drugs Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Pet Skin Disease Drugs Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Pet Skin Disease Drugs Sale Price by Type (2020-2025)
2.4 Pet Skin Disease Drugs Segment by Application
2.4.1 Parasitic Skin Diseases
2.4.2 Fungal Dermatoses
2.4.3 Bacterial Skin Diseases
2.4.4 Other
2.5 Pet Skin Disease Drugs Sales by Application
2.5.1 Global Pet Skin Disease Drugs Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Pet Skin Disease Drugs Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Pet Skin Disease Drugs Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Pet Skin Disease Drugs Breakdown Data by Company
3.1.1 Global Pet Skin Disease Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Pet Skin Disease Drugs Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Pet Skin Disease Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Pet Skin Disease Drugs Revenue by Company (2020-2025)
3.2.2 Global Pet Skin Disease Drugs Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Pet Skin Disease Drugs Sale Price by Company
3.4 Key Manufacturers Pet Skin Disease Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pet Skin Disease Drugs Product Location Distribution
3.4.2 Players Pet Skin Disease Drugs Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Pet Skin Disease Drugs by Geographic Region
4.1 World Historic Pet Skin Disease Drugs 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Pet Skin Disease Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pet Skin Disease Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pet Skin Disease Drugs 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Pet Skin Disease Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pet Skin Disease Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pet Skin Disease Drugs Sales Growth
4.4 APAC Pet Skin Disease Drugs Sales Growth
4.5 Europe Pet Skin Disease Drugs Sales Growth
4.6 Middle East & Africa Pet Skin Disease Drugs Sales Growth
5 Americas
5.1 Americas Pet Skin Disease Drugs Sales by Country
5.1.1 Americas Pet Skin Disease Drugs Sales by Country (2020-2025)
5.1.2 Americas Pet Skin Disease Drugs Revenue by Country (2020-2025)
5.2 Americas Pet Skin Disease Drugs Sales by Type (2020-2025)
5.3 Americas Pet Skin Disease Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pet Skin Disease Drugs Sales by Region
6.1.1 APAC Pet Skin Disease Drugs Sales by Region (2020-2025)
6.1.2 APAC Pet Skin Disease Drugs Revenue by Region (2020-2025)
6.2 APAC Pet Skin Disease Drugs Sales by Type (2020-2025)
6.3 APAC Pet Skin Disease Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Pet Skin Disease Drugs by Country
7.1.1 Europe Pet Skin Disease Drugs Sales by Country (2020-2025)
7.1.2 Europe Pet Skin Disease Drugs Revenue by Country (2020-2025)
7.2 Europe Pet Skin Disease Drugs Sales by Type (2020-2025)
7.3 Europe Pet Skin Disease Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pet Skin Disease Drugs by Country
8.1.1 Middle East & Africa Pet Skin Disease Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pet Skin Disease Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Pet Skin Disease Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Pet Skin Disease Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pet Skin Disease Drugs
10.3 Manufacturing Process Analysis of Pet Skin Disease Drugs
10.4 Industry Chain Structure of Pet Skin Disease Drugs
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pet Skin Disease Drugs Distributors
11.3 Pet Skin Disease Drugs Customer
12 World Forecast Review for Pet Skin Disease Drugs by Geographic Region
12.1 Global Pet Skin Disease Drugs 麻豆原创 Size Forecast by Region
12.1.1 Global Pet Skin Disease Drugs Forecast by Region (2026-2031)
12.1.2 Global Pet Skin Disease Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pet Skin Disease Drugs Forecast by Type (2026-2031)
12.7 Global Pet Skin Disease Drugs Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Zoetis Animal Health
13.1.1 Zoetis Animal Health Company Information
13.1.2 Zoetis Animal Health Pet Skin Disease Drugs Product Portfolios and Specifications
13.1.3 Zoetis Animal Health Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Zoetis Animal Health Main Business Overview
13.1.5 Zoetis Animal Health Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Pet Skin Disease Drugs Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 Elanco
13.3.1 Elanco Company Information
13.3.2 Elanco Pet Skin Disease Drugs Product Portfolios and Specifications
13.3.3 Elanco Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Elanco Main Business Overview
13.3.5 Elanco Latest Developments
13.4 Virbac
13.4.1 Virbac Company Information
13.4.2 Virbac Pet Skin Disease Drugs Product Portfolios and Specifications
13.4.3 Virbac Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Virbac Main Business Overview
13.4.5 Virbac Latest Developments
13.5 Norbrook Laboratories
13.5.1 Norbrook Laboratories Company Information
13.5.2 Norbrook Laboratories Pet Skin Disease Drugs Product Portfolios and Specifications
13.5.3 Norbrook Laboratories Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Norbrook Laboratories Main Business Overview
13.5.5 Norbrook Laboratories Latest Developments
13.6 Dechra Veterinary Products
13.6.1 Dechra Veterinary Products Company Information
13.6.2 Dechra Veterinary Products Pet Skin Disease Drugs Product Portfolios and Specifications
13.6.3 Dechra Veterinary Products Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Dechra Veterinary Products Main Business Overview
13.6.5 Dechra Veterinary Products Latest Developments
13.7 Vetoquinol
13.7.1 Vetoquinol Company Information
13.7.2 Vetoquinol Pet Skin Disease Drugs Product Portfolios and Specifications
13.7.3 Vetoquinol Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Vetoquinol Main Business Overview
13.7.5 Vetoquinol Latest Developments
13.8 ALKINLAB
13.8.1 ALKINLAB Company Information
13.8.2 ALKINLAB Pet Skin Disease Drugs Product Portfolios and Specifications
13.8.3 ALKINLAB Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 ALKINLAB Main Business Overview
13.8.5 ALKINLAB Latest Developments
13.9 Truseb
13.9.1 Truseb Company Information
13.9.2 Truseb Pet Skin Disease Drugs Product Portfolios and Specifications
13.9.3 Truseb Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Truseb Main Business Overview
13.9.5 Truseb Latest Developments
13.10 Olewo
13.10.1 Olewo Company Information
13.10.2 Olewo Pet Skin Disease Drugs Product Portfolios and Specifications
13.10.3 Olewo Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Olewo Main Business Overview
13.10.5 Olewo Latest Developments
13.11 KANGZHIBO
13.11.1 KANGZHIBO Company Information
13.11.2 KANGZHIBO Pet Skin Disease Drugs Product Portfolios and Specifications
13.11.3 KANGZHIBO Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 KANGZHIBO Main Business Overview
13.11.5 KANGZHIBO Latest Developments
13.12 Shanghai Hanvet Bio-Pharm
13.12.1 Shanghai Hanvet Bio-Pharm Company Information
13.12.2 Shanghai Hanvet Bio-Pharm Pet Skin Disease Drugs Product Portfolios and Specifications
13.12.3 Shanghai Hanvet Bio-Pharm Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Shanghai Hanvet Bio-Pharm Main Business Overview
13.12.5 Shanghai Hanvet Bio-Pharm Latest Developments
13.13 DCVET
13.13.1 DCVET Company Information
13.13.2 DCVET Pet Skin Disease Drugs Product Portfolios and Specifications
13.13.3 DCVET Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 DCVET Main Business Overview
13.13.5 DCVET Latest Developments
13.14 Nanjing LANBOTO
13.14.1 Nanjing LANBOTO Company Information
13.14.2 Nanjing LANBOTO Pet Skin Disease Drugs Product Portfolios and Specifications
13.14.3 Nanjing LANBOTO Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Nanjing LANBOTO Main Business Overview
13.14.5 Nanjing LANBOTO Latest Developments
13.15 Jindun Pharmaceutical
13.15.1 Jindun Pharmaceutical Company Information
13.15.2 Jindun Pharmaceutical Pet Skin Disease Drugs Product Portfolios and Specifications
13.15.3 Jindun Pharmaceutical Pet Skin Disease Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Jindun Pharmaceutical Main Business Overview
13.15.5 Jindun Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.